Armando Anido
2021
In 2021, Armando Anido earned a total compensation of $2.2M as Chairman of the Board and CEO at Zynerba Pharmaceuticals, a 49% increase compared to previous year.
Compensation breakdown
Non-Equity Incentive Plan | $379,675 |
---|---|
Option Awards | $446,472 |
Salary | $603,000 |
Stock Awards | $772,643 |
Other | $10,685 |
Total | $2,212,475 |
Anido received $772.6K in stock awards, accounting for 35% of the total pay in 2021.
Anido also received $379.7K in non-equity incentive plan, $446.5K in option awards, $603K in salary and $10.7K in other compensation.
Rankings
In 2021, Armando Anido's compensation ranked 5,662nd out of 12,415 executives tracked by ExecPay. In other words, Anido earned more than 54.4% of executives.
Classification | Ranking | Percentile |
---|---|---|
All | 5,662 | 54th |
Manufacturing | 2,399 | 56th |
Chemicals And Allied Products | 1,044 | 56th |
Drugs | 932 | 56th |
Pharmaceutical Preparations | 671 | 57th |
Anido's colleagues
We found two more compensation records of executives who worked with Armando Anido at Zynerba Pharmaceuticals in 2021.
News
Zynerba Pharmaceuticals CEO Armando Anido's 2022 pay slips 15% to $1.9M
April 21, 2023
Zynerba Pharmaceuticals CEO Armando Anido's 2021 pay jumps 49% to $2.2M
April 25, 2022
Zynerba Pharmaceuticals CEO Armando Anido's 2020 pay rises 8% to $1.5M
April 21, 2021
Zynerba Pharmaceuticals CEO Armando Anido's 2019 pay falls 32% to $1.4M
April 23, 2020
Zynerba Pharmaceuticals CEO Armando Anido's 2018 pay slips 18% to $2M
April 25, 2019